A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Conditions

• Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Imprime PGG — DRUG
• Rituximab — DRUG

Study Details

This research study is evaluating a drug combination called Imprime PGG and Rituximab as a possible treatment for relapsed/refractory indolent B cell non-Hodgkin lymphomas (NHL).

Key Dates

Start date

Dec 31, 2014

Status verified

Mar 2026

Primary completion

Jul 11, 2019

Completion

Feb 1, 2021

Study Design

Enrollment

25 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Imprime PGG and Rituximab
  The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment

Primary Outcome Measure

Overall Response Rate [ Time Frame: Response assessed at week 14 of study calendar (10 weeks after the 4-week treatment regimen). ]

Locations (1)

Find similar trials in Boston, MA